| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Sign In to gain access to subscriptions and/or personal tools.
|
|
|
|||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
Articles |
This study evaluated the steady-state pharmacokinetics and dose proportionality of troglitazone, metabolite 1 (sulfate conjugate), and metabolite 3 (quinone metabolite) following administration of daily oral doses of 200, 400, and 600 mg troglitazone for 7 days (per dosing period) to 21 subjects. During each dosing period, plasma samples were collected predose on days 1, 5, 6 and 7 and serially for 24 hours on day 7. Steady-state plasma concentrations for troglitazone, metabolite 1, and metabolite 3 were achieved by day 7. Troglitazone was rapidly absorbed with mean tmax values of 2.7 to 2.9 hours. Mean Cmax and AUC(0-24) values for troglitazone, metabolite 1, and metabolite 3 increased proportionally with increasing troglitazone doses over the clinical dose range of 200 mg to 600 mg administered once daily. Mean troglitazone CL/F, percent fluctuation, and AUC ratios of metabolite 1 and metabolite 3 to troglitazone were similar across dose groups. These data suggest that the pharmacokinetics and disposition of troglitazone and its metabolites are independent of dose over the dose range studied. Thus, troglitazone, metabolite 1, and metabolite 3 displayed linear pharmacokinetics at steady-state.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Watanabe, M. Nakajima, and T. Yokoi Troglitazone Glucuronidation in Human Liver and Intestine Microsomes: High Catalytic Activity of UGT1A8 and UGT1A10 Drug Metab. Dispos., December 1, 2002; 30(12): 1462 - 1469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Honma, M. Shimada, H. Sasano, S. Ozawa, M. Miyata, K. Nagata, T. Ikeda, and Y. Yamazoe Phenol Sulfotransferase, ST1A3, as the Main Enzyme Catalyzing Sulfation of Troglitazone in Human Liver Drug Metab. Dispos., August 1, 2002; 30(8): 944 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Veldhuis, G. Zhang, and J. C. Garmey Troglitazone, an Insulin-Sensitizing Thiazolidinedione, Represses Combined Stimulation by LH and Insulin of de Novo Androgen Biosynthesis by Thecal Cells in Vitro J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1129 - 1133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yamamoto, H. Yamazaki, T. Ikeda, T. Watanabe, H. Iwabuchi, M. Nakajima, and T. Yokoi Formation of a Novel Quinone Epoxide Metabolite of Troglitazone with Cytotoxic to HepG2 Cells Drug Metab. Dispos., February 1, 2002; 30(2): 155 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. E. Kostrubsky, M. Vore, E. Kindt, J. Burliegh, K. Rogers, G. Peter, D. Altrogge, and M. W. Sinz The Effect of Troglitazone Biliary Excretion on Metabolite Distribution and Cholestasis in Transporter-Deficient Rats Drug Metab. Dispos., December 1, 2001; 29(12): 1561 - 1566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. E. Kostrubsky, J. F. Sinclair, V. Ramachandran, R. Venkataramanan, Y. H. Wen, E. Kindt, V. Galchev, K. Rose, M. Sinz, and S. C. Strom The Role of Conjugation in Hepatotoxicity of Troglitazone in Human and Porcine Hepatocyte Cultures Drug Metab. Dispos., October 1, 2000; 28(10): 1192 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Arlt, R. J. Auchus, and W. L. Miller Thiazolidinediones but Not Metformin Directly Inhibit the Steroidogenic Enzymes P450c17 and 3beta -Hydroxysteroid Dehydrogenase J. Biol. Chem., May 11, 2001; 276(20): 16767 - 16771. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
